The U.S. prostate cancer treatment devices market attained a value of $95.9 million in 2019 and is predicted to grow at a CAGR of 5.6% between 2020 and 2030, to reach a valuation of $157.1 million.
The main factors driving the progress of the market are the increasing number of prostate cancer cases being recorded in the country every year.
The high prevalence of this diseases is predicted to push up the demand for various treatment devices and equipment such as cryotherapy, surgery, and radiotherapy in the future years, thereby causing the expansion of the U.S. prostate cancer treatment devices market. Apart from this, the increasing number of government initiatives being implemented in the country is also fueling the market advancement. The federal government spends a huge portion of the country's GDP on healthcare every year.
As per the reports of the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. increased by as much as 4.3% and reached $3.3 trillion in 2016. This percentage further grew to 5.4% in 2017. The soaring healthcare expenditure is making the management and treatment of various diseases more affordable than they were before, which is, in turn, fueling the expansion of the U.S. prostate cancer treatment devices market.
Thus, it can be said with certainty that the market would demonstrate substantial growth in the upcoming years, mainly because of the rising incidence of prostate cancer and the surging government spending on healthcare in the country.
Key Topics Covered:
Chapter 1. Research Background
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Introduction 4.1 Definition of Market Segments 4.1.1 By Type 184.108.40.206 Radiation 220.127.116.11.1 Clinical trials 18.104.22.168 Surgery 22.214.171.124.1 Clinical trials 126.96.36.199 HIFU 188.8.131.52.1 Clinical trials 184.108.40.206 Cryotherapy 220.127.116.11.1 Clinical trials 18.104.22.168 Others 4.1.2 By End User 22.214.171.124 Hospitals 126.96.36.199 Specialty centers 188.8.131.52 Others 4.2 Market Dynamics 4.2.1 Trends 184.108.40.206 Adoption of robotic prostatectomy 220.127.116.11 Accelerating evolution in radiotherapy techniques 4.2.2 Drivers 18.104.22.168 Technological advancements 22.214.171.124 Increasing prevalence of prostate cancer 126.96.36.199 Rising number of government initiatives 188.8.131.52 Surging geriatric population 184.108.40.206 Impact analysis of drivers on market forecast 4.2.3 Restraints 220.127.116.11 Longer approval time for prostate cancer devices 18.104.22.168 Challenges in identifying molecular predictors of response to radiotherapy 22.214.171.124 Impact analysis of drivers on market forecast 4.2.4 Opportunities 126.96.36.199 Positioning devices to improve treatment and patient experience 4.3 COVID-19 Impact on U.S. Prostate Cancer Treatment Devices Market 4.3.1 Supply Side Analysis 4.3.2 Demand Side Analysis 4.4 Porter's Five Forces Analysis 4.5 Therapy Comparison 4.5.1 HIFU Therapy 4.5.2 Surgery Vs Radiation Therapy 4.5.3 Cryotherapy 4.6 Average Pricing of Devices
Chapter 5. U.S. Market Size and Forecast 5.1 By Type 5.2 By End User 5.3 By State
Chapter 6. Competitive Landscape 6.1 Product Benchmarking of Key Players 6.2 Strategic Developments of Key Players 6.2.1 Approvals and Product Launch 6.2.2 Mergers and Acquisitions 6.2.3 Other Developments
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites